The Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Increasing Investments in Pharmaceutical R&D and Increasing Demand for Biological are Driving the Market Growth
Research is substantially funded in the pharmaceutical industry, with forward-thinking businesses allocating 15% of their sales on average to R&D. Due to a growth in R&D investment on early-stage development and the volume of potential drugs at the preclinical stage, preclinical services are also in high demand among life science firms.Many pharmaceutical companies have increased their R&D spending to help with the development of new medicines and therapies. In 2022, the largest pharmaceutical firms, including Roche, Pfizer, Merck, and Bristol-Myers Squibb, would devote about one-fifth of their annual revenue to R&D efforts. As a result of the surge in pharmaceutical R&D spending, it is projected that the need for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs will expand, providing CMOs with more opportunities to provide outsourcing services.
As a result, many people have investigated cost-cutting options, like outsourcing manufacturing. As more patents are slated to expire, more efforts are being made to uncover biologics and novel chemicals, and the expense of R&D is rising, drug makers and sponsors are under greater pressure to make up for the financial losses brought on by generics. This is making drug research even more expensive and complex. Even government organisations are turning to CROs to outsource their clinical production in order to have access to the necessary tools and expertise, as well as to cut costs and outsourcing timelines.
High Operational Costs Likely to Challenge Industry Growth
The high operational costs are impeding the rise of global revenue. Use of advanced equipment is necessary while producing sterile medications. For instance, a biotechnology business may need to create 3,000 vials of an injectable medicine (sterile fill and finish) in order to carry out a phase I–II clinical study in oncology. The projected costs to manufacture pharmaceutical items are as follows: project planning & management: $35,000; supplier management: $4,000; and drug product analytical development: $40,000. It is believed that the biotechnology company will assign the production task to a different contract drug manufacturing organization (CDMO). Furthermore, due to FDA requirements mandating extreme attention be taken in the manufacturing, packaging, storage, and distribution of sterile injectable pharmaceuticals, the operational cost burden is significant, which can hamper the CMO market growth.
What Questions Should You Ask Before Buying a Market Research Report?
• How is the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market evolving?
• What is driving and restraining the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market?
• How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market?
• Where is the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market today, and over the next 10 years:
• Our 428-page report provides 170 tables, 254 charts, and graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Molecule Type
• Small Molecules
• Large Molecules
Type
• Monoclonal Antibodies
• Cytokines
• Insulin
• Peptide Hormones
• Vaccines
• Immunoglobulins
• Blood Factors
• Peptide Antibiotics
• Other Types
Application
• Cancer
• Diabetes
• Cardiovascular diseases
• CNS
• Infectious
• Others
Container Type
• Bottles
• Ampoules
• Vials
• Prefilled syringes
• Bags
Route of Administration
• Subcutaneous
• Intravenous
• Intramuscular
• Other Route of Administration
Service
• Bioanalytical Testing
• Method Development & Validation
• Stability Testing
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Italy
• Spain
• Switzerland
• Netherlands
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
MEA
• GCC
• South Africa
• Egypt
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Adare Pharma Solutions
• Aenova Group
• Almac Group
• Avara Pharmaceutical Services, Inc.
• Boehringer Ingelheim International GmbH
• Catalent, Inc.
• CordenPharma International
• Evonik Industries AG
• F. Hoffmann-La Roche Ltd.
• FAMAR Health Care Services
• Fresenius Kabi AG
• Grifols, S.A.
• Hikma Pharmaceuticals PLC
• Jubilant Pharmova Limited
• Lilly
• Lonza
• Nexus Pharmaceuticals, LLC
• Patheon Pharma Services (Thermo Fisher Scientific Inc.)
• Pfizer Inc.
• Piramal Pharma Solutions
• Recipharm AB
• Siegfried Holding AG
• Vetter Pharma
• Wuxi AppTec
Overall world revenue for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 in terms of value the market will surpass US$24.2 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 report help you?
In summary, our 420+ page report provides you with the following knowledge:
• Revenue forecasts to 2034 for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market, with forecasts for type, molecule type, application, container type, route of administration, services, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 21 key national markets – See forecasts for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 25 of the major companies involved in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034: Forecasts by Molecule Type (Small Molecules, Large Molecules), by Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Peptide Antibiotics, Other), by Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Other), by Container Type (Bottles, Ampoules, Vials, Pre-filled Syringes, Bags), by Route of Administration (Subcutaneous, Intravenous, Intramuscular, Other), by Service (Bioanalytical Testing, Method Development & Validation, Stability Testing, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to CMO of Sterile Injectable Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Growing Focus on Development to Treat Cancer
3.2.1.2 Rising Prevalence of Chronic Diseases
3.2.1.3 Rapid FDA Approvals of Sterile Injectable Drugs to Fuel Market Growth
3.2.1.4 As Manufacturers Invest in New Manufacturing Facilities, The Demand for Sterile Injectable is expected to Rise
3.2.1.5 Increasing Demand for Biological is Expected to Drive the Demand
3.2.1.6 Increasing Investments in Pharmaceutical R&D
3.2.2 Market Restraining Factors
3.2.2.1 Growing Competition from Small Manufacturers
3.2.2.2 High Operational Costs
3.2.2.3 Inadequate Healthcare Infrastructure Across Developing Economies Challenging Market Growth
3.2.3 Market Opportunities
3.2.3.1 Prefilled Syringes to Offer Lucrative Growth Prospects
3.2.3.2 Growing Investments
3.2.3.3 Expanding Clinical Trial Opportunities in the Asia Pacific Region
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Competitive Rivalry
3.4.2 Threat of New Entrants
3.4.3 Threat of Substitutes
3.4.4 Bargaining Power of Buyers
3.4.5 Bargaining Power of Suppliers
3.5 SWOT Analysis
3.6 PEST Analysis
3.6.1 Political Factors Impacting CMO of Sterile Injectable Drugs Market
3.6.2 Economic Factors Impacting CMO of Sterile Injectable Drugs Market
3.6.3 Social Factors Impacting CMO of Sterile Injectable Drugs Market
3.6.4 Technological Factors Impacting CMO of Sterile Injectable Drugs Market
4 CMO of Sterile Injectable Drugs Market Analysis by Molecule Type
4.1 Key Findings
4.2 Molecule Type Segment: Market Attractiveness Index
4.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
4.4 Small Molecule
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Large Molecule
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, by Type, 2024-2034
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, by Type
5.4 Monoclonal Antibodies (mAbs)
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Cytokines
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Insulin
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Peptide Hormones
5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Vaccines
5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
5.8.2 Market Share by Region, 2024 & 2034 (%)
5.9 Immunoglobulins
5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
5.9.2 Market Share by Region, 2024 & 2034 (%)
5.10 Blood Factor
5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
5.10.2 Market Share by Region, 2024 & 2034 (%)
5.11 Peptide Antibiotics
5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
5.11.2 Market Share by Region, 2024 & 2034 (%)
5.12 Other Type
5.12.1 Market Size by Region, 2024-2034 (US$ Billion)
5.12.2 Market Share by Region, 2024 & 2034 (%)
6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application
6.1 Key Findings
6.2 Application Segment: Market Attractiveness Index
6.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
6.4 Cancer
6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Diabetes
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Cardiovascular Diseases
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 CNS
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Infectious
6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
6.8.2 Market Share by Region, 2024 & 2034 (%)
6.9 Others
6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
6.9.2 Market Share by Region, 2024 & 2034 (%)
7 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type
7.1 Key Findings
7.2 Container Type Segment: Market Attractiveness Index
7.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
7.4 Bottles
7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Ampoules
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Vials
7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Prefilled Syringes
7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
7.7.2 Market Share by Region, 2024 & 2034 (%)
7.8 Bags
7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
7.8.2 Market Share by Region, 2024 & 2034 (%)
8 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
8.4 Subcutaneous
8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
8.4.2 Market Share by Region, 2024 & 2034 (%)
8.5 Intravenous
8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Intramuscular
8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
8.6.2 Market Share by Region, 2024 & 2034 (%)
8.7 Other Route of Administration
8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
8.7.2 Market Share by Region, 2024 & 2034 (%)
9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service
9.1 Key Findings
9.2 Service Segment: Market Attractiveness Index
9.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
9.4 Bioanalytical Testing
9.4.1 Market Size by Region, 2024-2034 (US$ Billion)
9.4.2 Market Share by Region, 2024 & 2034 (%)
9.5 Method Development & Validation
9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
9.5.2 Market Share by Region, 2024 & 2034 (%)
9.6 Stability Testing
9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
9.6.2 Market Share by Region, 2024 & 2034 (%)
9.7 Others
9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
9.7.2 Market Share by Region, 2024 & 2034 (%)
10 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast
11 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
11.1 Key Findings
11.2 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
11.3 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
11.5 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
11.6 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
11.7 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
11.8 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
11.9 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
11.10 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
11.11 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
11.12 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.1 Key Findings
12.2 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
12.3 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
12.5 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
12.6 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
12.7 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
12.8 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
12.9 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
12.10 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
12.11 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.12 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.13 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.14 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.15 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.16 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.17 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.18 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.1 Key Findings
13.2 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
13.3 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
13.5 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
13.6 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
13.7 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
13.8 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
13.9 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
13.10 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
13.11 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.12 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.13 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.14 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.15 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.16 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.17 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14.1 Key Findings
14.2 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
14.3 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
14.4 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
14.5 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
14.6 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
14.7 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
14.8 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
14.9 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
14.10 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
14.11 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14.12 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14.13 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14.14 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15.1 Key Findings
15.2 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
15.3 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
15.4 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
15.5 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
15.6 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
15.7 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
15.8 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
15.9 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
15.10 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
15.11 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15.12 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15.13 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15.14 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
16 Company Profiles
16.1 Competitive Landscape, 2022
16.2 Aenova Group
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Financial Analysis
16.2.3.1 Net Revenue, 2018-2022
16.2.3.2 Segment Market Shares, 2022
16.2.3.3 Regional Market Shares, 2022
16.2.4 Service Benchmarking
16.2.5 Strategic Outlook
16.3 Almac Group
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Service Benchmarking
16.3.4 Strategic Outlook
16.4 WuXi AppTec
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2018-2022
16.4.3.2 R&D, 2018-2022
16.4.3.3 Segment Market Shares, 2022
16.4.3.4 Regional Market Shares, 2022
16.4.4 Service Benchmarking
16.4.5 Strategic Outlook
16.5 Boehringer Ingelheim International GmbH
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2018-2022
16.5.3.2 Segment Market Shares, 2022
16.5.3.3 Regional Market Shares, 2022
16.5.4 Service Benchmarking
16.5.5 Strategic Outlook
16.6 Catalent, Inc.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2018-2022
16.6.3.2 Segment Market Shares, 2022
16.6.3.3 Regional Market Shares, 2022
16.6.4 Service Benchmarking
16.6.5 Strategic Outlook
16.7 CordenPharma International
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Service Benchmarking
16.7.4 Strategic Outlook
16.8 Evonik Industries AG
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Net Revenue, 2018-2022
16.8.3.2 R&D, 2018-2022
16.8.3.3 Segment Market Shares, 2022
16.8.3.4 Regional Market Shares, 2022
16.8.4 Service Benchmarking
16.8.5 Strategic Outlook
16.9 FAMAR Health Care Services
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Service Benchmarking
16.9.4 Strategic Outlook
16.10 Fresenius Kabi AG
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2018-2022
16.10.3.2 R&D, 2018-2022
16.10.3.3 Segment Market Shares, 2022
16.10.3.4 Regional Market Shares, 2022
16.10.4 Service Benchmarking
16.10.5 Strategic Outlook
16.11 Grifols, S.A.
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Net Revenue, 2018-2022
16.11.3.2 R&D, 2018-2022
16.11.3.3 Segment Market Shares, 2022
16.11.3.4 Regional Market Shares, 2022
16.11.4 Service Benchmarking
16.11.5 Strategic Outlook
16.12 Hikma Pharmaceuticals PLC
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Financial Analysis
16.12.3.1 Net Revenue, 2018-2022
16.12.3.2 R&D, 2018-2022
16.12.3.3 Segment Market Shares, 2022
16.12.3.4 Regional Market Shares, 2022
16.12.4 Service Benchmarking
16.12.5 Strategic Outlook
16.13 Jubilant Pharmova Limited
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.3.1 Net Revenue, 2018-2022
16.13.3.2 Segment Market Shares, 2022
16.13.3.3 Regional Market Shares, 2022
16.13.4 Service Benchmarking
16.13.5 Strategic Outlook
16.14 Lonza
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Net Revenue, 2018-2022
16.14.3.2 R&D, 2018-2022
16.14.3.3 Segment Market Shares, 2022
16.14.3.4 Regional Market Shares, 2022
16.14.4 Service Benchmarking
16.14.5 Strategic Outlook
16.15 Patheon Pharma Services (Thermo Fisher Scientific Inc.)
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Financial Analysis
16.15.3.1 Net Revenue, 2018-2022
16.15.3.2 R&D, 2018-2022
16.15.3.3 Segment Market Shares, 2022
16.15.3.4 Regional Market Shares, 2022
16.15.4 Service Benchmarking
16.15.5 Strategic Outlook
16.16 Pfizer Inc.
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Financial Analysis
16.16.3.1 Net Revenue, 2018-2022
16.16.3.2 R&D, 2018-2022
16.16.3.3 Segment Market Shares, 2022
16.16.3.4 Regional Market Shares, 2022
16.16.4 Service Benchmarking
16.16.5 Strategic Outlook
16.17 Recipharm AB
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Financial Analysis
16.17.3.1 Net Revenue, 2018-2022
16.17.4 Service Benchmarking
16.17.5 Strategic Outlook
16.18 Siegfried Holding AG
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Financial Analysis
16.18.3.1 Net Revenue, 2018-2022
16.18.3.2 R&D, 2018-2022
16.18.3.3 Segment Market Shares, 2022
16.18.4 Service Benchmarking
16.18.5 Strategic Outlook
16.19 Nexus Pharmaceuticals, LLC
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.3 Service Benchmarking
16.19.4 Strategic Outlook
16.20 Avara Pharmaceutical Services, Inc.
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Service Benchmarking
16.21 Lilly
16.21.1 Company Snapshot
16.21.2 Company Overview
16.21.3 Financial Analysis
16.21.3.1 Net Revenue, 2018-2022
16.21.3.2 R&D, 2018-2022
16.21.3.3 Regional Market Shares, 2022
16.21.4 Service Benchmarking
16.21.5 Strategic Outlook
16.22 Adare Pharma Solutions
16.22.1 Company Snapshot
16.22.2 Company Overview
16.22.3 Service Benchmarking
16.22.4 Strategic Outlook
16.23 Vetter Pharma
16.23.1 Company Snapshot
16.23.2 Company Overview
16.23.3 Service Benchmarking
16.23.4 Strategic Outlook
16.24 Piramal Pharma Solutions
16.24.1 Company Snapshot
16.24.2 Company Overview
16.24.3 Service Benchmarking
16.24.4 Strategic Outlook
17 Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players
List of Tables
Table 1 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 7 Small Molecule Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Large Molecule Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Monoclonal Antibodies (mAbs) Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Cytokines Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Insulin Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Peptide Hormones Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Vaccines Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Immunoglobulins Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Blood Factor Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Peptide Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Other Type Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Diabetes Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 CNS Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Infectious Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Bottles Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 AMPOULES Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Vials Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Prefilled Syringes Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Bags Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Intravenous Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Intramuscular Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 Other Route of Administration Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Bioanalytical Testing Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 Method Development & Validation Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 Stability Testing Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 83 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 84 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 85 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 86 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 87 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 88 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 89 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 90 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 91 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 92 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 93 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 94 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 95 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 96 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 97 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 98 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 99 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 100 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 101 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 102 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 103 Aenova Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Aenova Group: Service Benchmarking
Table 105 Aenova Group: Strategic Outlook
Table 106 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Almac Group: Service Benchmarking
Table 108 Almac Group: Strategic Outlook
Table 109 WuXi AppTec : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 WuXi AppTec : Service Benchmarking
Table 111 WuXi AppTec : Strategic Outlook
Table 112 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Boehringer Ingelheim International GmbH: Service Benchmarking
Table 114 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 115 Catalent, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Catalent, Inc. : Service Benchmarking
Table 117 Catalent, Inc. : Strategic Outlook
Table 118 CordenPharma International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 CordenPharma International: Service Benchmarking
Table 120 CordenPharma International: Strategic Outlook
Table 121 Evonik Industries AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Evonik Industries AG: Service Benchmarking
Table 123 Evonik Industries AG: Strategic Outlook
Table 124 FAMAR Health Care Services: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 FAMAR Health Care Services.: Service Benchmarking
Table 126 FAMAR Health Care Services.: Strategic Outlook
Table 127 Fresenius Kabi AG : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Fresenius Kabi AG: Service Benchmarking
Table 129 Fresenius Kabi AG: Strategic Outlook
Table 130 Grifols, S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Grifols, S.A.: Service Benchmarking
Table 132 Grifols, S.A.: Strategic Outlook
Table 133 Hikma Pharmaceuticals PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Hikma Pharmaceuticals PLC: Service Benchmarking
Table 135 Hikma Pharmaceuticals PLC: Strategic Outlook
Table 136 Jubilant Pharmova Limited : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Jubilant Pharmova Limited : Service Benchmarking
Table 138 Jubilant Pharmova Limited : Strategic Outlook
Table 139 Lonza : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 Lonza: Service Benchmarking
Table 141 Lonza: Strategic Outlook
Table 142 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Service Benchmarking
Table 144 Patheon Pharma Services (Thermo Fisher Scientific inc.): Strategic Outlook
Table 145 Pfizer Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Pfizer Inc.: Service Benchmarking
Table 147 Pfizer Inc.: Strategic Outlook
Table 148 Recipharm AB : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Recipharm AB: Service Benchmarking
Table 150 Recipharm AB: Strategic Outlook
Table 151 Siegfried Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 152 Siegfried Holding AG: Service Benchmarking
Table 153 Recipharm AB: Strategic Outlook
Table 154 Nexus Pharmaceuticals, LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 Nexus Pharmaceuticals, LLC: Service Benchmarking
Table 156 Nexus Pharmaceuticals, LLC: Strategic Outlook
Table 157 Avara Pharmaceutical Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 158 Avara Pharmaceutical Services, Inc.: Service Benchmarking
Table 159 Lilly: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 160 Lilly: Service Benchmarking
Table 161 Lilly: Strategic Outlook
Table 162 Adare Pharma Solutions.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 163 Adare Pharma Solutions.: Service Benchmarking
Table 164 Adare Pharma Solutions.: Strategic Outlook
Table 165 Vetter Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 166 Vetter Pharma: Service Benchmarking
Table 167 Vetter Pharma: Strategic Outlook
Table 168 Piramal Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 169 Piramal Pharma Solutions: Service Benchmarking
Table 170 Piramal Pharma Solutions: Strategic Outlook
List of Figures
Figure 1 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Segmentation
Figure 2 Contract Manufacturing Outsourcing (CMO) Market Attractiveness Index by Region
Figure 3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Molecule Type: Market Attractiveness Index
Figure 4 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type: Market Attractiveness Index
Figure 5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application: Market Attractiveness Index
Figure 6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type: Market Attractiveness Index
Figure 7 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration: Market Attractiveness Index
Figure 8 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service: Market Attractiveness Index
Figure 9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Market Dynamics
Figure 10 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 11 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 12 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 13 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 14 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Porter’s Five Forces Analysis
Figure 15 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: SWOT Analysis
Figure 16 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: PEST Analysis
Figure 17 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Molecule Type: Market Attractiveness Index
Figure 18 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR %)
Figure 19 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024, 2029, 2034 (%)
Figure 20 Small Molecule Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 21 Small Molecule Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Large Molecule Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 23 Large Molecule Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type: Market Attractiveness Index
Figure 25 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type, 2024-2034 (US$ Billion)
Figure 26 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 27 Monoclonal Antibodies (mAbs) Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 28 Monoclonal Antibodies (mAbs) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Cytokines Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 30 Cytokines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Insulin Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 32 Insulin Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Peptide Hormones Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 34 Peptide Hormones Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Vaccines Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 36 Vaccines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Immunoglobulins Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 38 Immunoglobulins Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Blood Factor Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 40 Blood Factor Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Peptide Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 42 Peptide Antibiotics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Other Type Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 44 Other Type Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application: Market Attractiveness Index
Figure 46 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 47 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 48 Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 49 Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Diabetes Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 51 Diabetes Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 53 Cardiovascular Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 CNS Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 55 CNS Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Infectious Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 57 Infectious Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Others Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 59 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type: Market Attractiveness Index
Figure 61 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 62 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024, 2029, 2034 (%)
Figure 63 Bottles Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 64 Bottles Market Share Forecast by Region, 2024 & 2034 (%)
Figure 65 AMPOULES Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 66 AMPOULES Market Share Forecast by Region, 2024 & 2034 (%)
Figure 67 Vials Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 68 Vials Market Share Forecast by Region, 2024 & 2034 (%)
Figure 69 Prefilled Syringes Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 70 Prefilled Syringes Market Share Forecast by Region, 2024 & 2034 (%)
Figure 71 Bags Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 72 Bags Market Share Forecast by Region, 2024 & 2034 (%)
Figure 73 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration: Market Attractiveness Index
Figure 74 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 75 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 76 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 77 Subcutaneous Market Share Forecast by Region, 2024 & 2034 (%)
Figure 78 Intravenous Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 79 Intravenous Market Share Forecast by Region, 2024 & 2034 (%)
Figure 80 Intramuscular Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 81 Intramuscular Market Share Forecast by Region, 2024 & 2034 (%)
Figure 82 Other Route of Administration Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 83 Other Route of Administration Market Share Forecast by Region, 2024 & 2034 (%)
Figure 84 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service: Market Attractiveness Index
Figure 85 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 86 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024, 2029, 2034 (%)
Figure 87 Bioanalytical Testing Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 88 Bioanalytical Testing Market Share Forecast by Region, 2024 & 2034 (%)
Figure 89 Method Development & Validation Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 90 Method Development & Validation Market Share Forecast by Region, 2024 & 2034 (%)
Figure 91 Stability Testing Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 92 Stability Testing Market Share Forecast by Region, 2024 & 2034 (%)
Figure 93 Others Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 94 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 95 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 96 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 97 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 98 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 99 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 100 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 101 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 102 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR %)
Figure 103 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 104 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 105 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 106 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 107 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 108 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR %)
Figure 109 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 110 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 111 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 112 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR %)
Figure 113 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 114 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 115 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 116 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 117 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 118 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 119 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 120 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 121 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 122 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 123 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 124 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 125 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034(%)
Figure 126 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 127 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034(%)
Figure 128 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 129 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034(%)
Figure 130 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 131 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034(%)
Figure 132 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 133 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 134 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 135 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 136 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 137 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 138 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 139 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 140 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 141 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 142 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 143 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 144 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 145 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 146 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 147 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 148 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 149 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 150 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 151 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 152 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 153 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 154 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 155 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 156 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 157 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 158 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 159 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 160 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 161 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 162 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 163 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 164 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 165 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 166 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 167 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 168 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 169 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 170 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 171 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 172 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 173 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 174 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 175 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 176 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 177 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 178 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 179 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 180 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 181 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 182 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 183 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 184 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 185 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 186 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 187 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 188 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 189 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 190 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 191 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 192 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 193 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 194 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 195 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 196 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 197 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 198 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 199 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 200 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 201 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 202 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 203 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Company Share/Ranking, 2022
Figure 204 Aenova Group: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 205 Aenova Group: Segment Market Shares, 2022
Figure 206 Aenova Group: Regional Market Shares, 2022
Figure 207 WuXi AppTec : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 208 WuXi AppTec : R&D, 2018-2022 (US$ Million, AGR %)
Figure 209 WuXi AppTec : Segment Market Shares, 2022
Figure 210 WuXi AppTec : Regional Market Shares, 2022
Figure 211 Boehringer Ingelheim International GmbH: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 212 Boehringer Ingelheim International GmbH: Segment Market Shares, 2022
Figure 213 Boehringer Ingelheim International GmbH: Regional Market Shares, 2022
Figure 214 Catalent, Inc. : Net Revenue, 2018-2022 (US$ Million, AGR (%)
Figure 215 Catalent, Inc. : Segment Market Shares, 2022
Figure 216 Catalent, Inc. : Regional Market Shares, 2022
Figure 217 Evonik Industries AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 218 Evonik Industries AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 219 Evonik Industries AG: Segment Market Shares, 2022
Figure 220 Evonik Industries AG: Regional Market Shares, 2022
Figure 221 Fresenius Kabi AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 222 Fresenius Kabi AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 223 Fresenius Kabi AG: Segment Market Shares, 2022
Figure 224 Fresenius Kabi AG: Regional Market Shares, 2022
Figure 225 Grifols, S.A. : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 226 Grifols, S.A.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 227 Grifols, S.A.: Segment Market Shares, 2022
Figure 228 Grifols, S.A.: Regional Market Shares, 2022
Figure 229 Hikma Pharmaceuticals Plc: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 230 Hikma Pharmaceuticals Plc: R&D, 2018-2022 (US$ Million, AGR %)
Figure 231 Hikma Pharmaceuticals Plc: Segment Market Shares, 2022
Figure 232 Hikma Pharmaceuticals Plc: Regional Market Shares, 2022
Figure 233 Jubilant Pharmova Limited: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 234 Jubilant Pharmova Limited : Segment Market Shares, 2022
Figure 235 Jubilant Pharmova Limited .: Regional Market Shares, 2022
Figure 236 Lonza : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 237 Lonza : R&D, 2018-2022 (US$ Million, AGR %)
Figure 238 Lonza : Segment Market Shares, 2022
Figure 239 Lonza : Regional Market Shares, 2022
Figure 240 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 241 Patheon Pharma Services (Thermo Fisher Scientific Inc.): R&D, 2018-2022 (US$ Million, AGR %)
Figure 242 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Segment Market Shares, 2022
Figure 243 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Regional Market Shares, 2022
Figure 244 Pfizer Inc. : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 245 Pfizer Inc.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 246 Pfizer Inc.: Segment Market Shares, 2022
Figure 247 Pfizer Inc.: Regional Market Shares, 2022
Figure 248 Recipharm AB: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 249 Siegfried Holding AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 250 Siegfried Holding AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 251 Siegfried Holding AG: Segment Market Shares, 2022
Figure 252 Lilly: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 253 Lilly: R&D, 2018-2022 (US$ Million, AGR %)
Figure 254 Lilly: Regional Market Shares, 2022
List of Companies Profiled in the Report
Adare Pharma Solutions
Aenova Group
Almac Group
Avara Pharmaceutical Services, Inc.
Boehringer Ingelheim International GmbH
Catalent, Inc.
CordenPharma International
Evonik Industries AG
F. Hoffmann-La Roche Ltd.
FAMAR Health Care Services
Fresenius Kabi AG
Grifols, S.A.
Hikma Pharmaceuticals PLC
Jubilant Pharmova Limited
Lilly
Lonza
Nexus Pharmaceuticals, LLC.
Patheon Pharma Services (Thermo Fisher Scientific Inc.)
Pfizer Inc.
Piramal Pharma Solutions
Recipharm AB
Siegfried Holding AG
Vetter Pharma
Wuxi AppTec
List of Other Companies Mentioned in the Report
Abbott Laboratories
Abexxa Biologics Inc.
Adare Pharma Solutions
Aesica Pharmaceuticals Limited
AGC Bio
AGC Pharma Chemicals
Akums Drugs & Pharmaceuticals Ltd.
Alcami
Almirall S.A.
ALSA Ventures
AMRI, Curia
ApiJect Systems, Corp
Arabio
Archimica S.p.A
Ardena Holding NV
Arranta Bio
Arsenal Biosciences
Asher Biotherapeutics, Inc. (Asher Bio)
Aspen Pharmacare
AstraZeneca
Atossa Therapeutics
Aurobindo Pharma
Bavarian Nordic
Bayer
Berkshire Sterile Manufacturing's (BSM)
Biohaven Pharmaceuticals
Biomedical Advanced Research and Development Authority (BARDA)
BioNTech SE
BioNxt Solutions Inc.
Bio-Thera Solutions, Ltd
CanSino Biologics
Celltrion Healthcare
Cenexi Group
Charles River Laboratories
Civica, Inc.
Clear Creek Bio
CorEvitas, LLC
CuraTeQ Biologics
Curigin
Custopharm Inc.
Daiichi Sankyo
Delpharm
Diabeloop
DICE Therapeutics
DiNAMIQS
Dr. Reddy's Laboratories Ltd
Eisai
Emergent BioSolutions
Evotec Biologics
Exelixis, Inc.
F. Hoffman-La Roche
Formulated Solutions
Gedeon Richter Plc. (“Richter”)
HaemaLogiX Ltd
ICON plc
IQVIA Holdings Inc.
Ivenix, Inc.
Moderna, Inc.
Novartis
Novo Nordisk
PCI Pharma Services
Pharmaceutical Product Development LLC
Sanofi
Serum Institute of India
Takara Bio
Takeda
Theratechnologies Inc.
Transpire Bio
Vertex Pharmaceuticals Incorporated
Ypsomed AG
ZEISS Medical Technology
List of Organizations Mentioned in the Report
American Heart Association
American University in Cairo (AUC)
Canadian Cancer Society
Central Drugs Standard Control Organisation (CSDCO)
Clinical Trials on Alzheimer's Congress (CTAD)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Global Research & Process Development Centre
Ministry of Health (MoH)
National Institutes of Health
National Medical Products Administration (NMPA)
PATH Vaccine Resource Library
The Austrian Agency for Health and Food Safety (AGES)
The European Medicines Agency (EMA)
The Mexican Institute of Social Security (IMSS)
The Occupational Safety and Health Administration (OSHA)
The Therapeutic Goods Administration (TGA)
U.S. Biomedical Advanced Research and Development Authority (BARDA)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
